More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.66B
EPS
0.14
P/E ratio
138.1
Price to sales
11.65
Dividend yield
--
Beta
-0.226827
Previous close
$96.31
Today's open
$99.12
Day's range
$94.11 - $100.01
52 week range
$61.96 - $150.44
show more
CEO
--
Employees
713
Headquarters
Menlo Park, CA
Exchange
Nasdaq Global Select
Shares outstanding
47774848
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
BillionToOne to Participate in the Piper Sandler 38th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Piper Sandler 38th Annual Healthcare Conference.
GlobeNewsWire • 4 hours ago

BillionToOne: 3 Key Takeaways for Long-Term Investors
BillionToOne raised 2026 revenue guidance to $460 million to $470 million. Third-quarter revenue reached $123 million, up 47% year over year.
The Motley Fool • Nov 15, 2026

BillionToOne, Inc. (BLLN) Presents at 2026 UBS Global Healthcare Conference Transcript
BillionToOne, Inc. ( BLLN ) 2026 UBS Global Healthcare Conference November 10, 2026 2:00 PM EST Company Participants Oguzhan Atay - Co-Founder, Chairman & CEO Presentation Unknown Analyst Good afternoon. I'm Doug Schenkel with UBS, and it's my pleasure to welcome Oguzhan Atay, Co-Founder and Chief Executive Officer of BillionToOne.
Seeking Alpha • Nov 11, 2026

Billiontoone Q3 Earnings Call Highlights
Billiontoone NASDAQ: BLLN raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics company also reported its fifth consecutive quarter of positive GAAP operating income.
MarketBeat • Nov 5, 2026

BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript
BillionToOne, Inc. (BLLN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

BillionToOne Reports Third Quarter 2026 Results and Raises 2026 Revenue Guidance
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026.
GlobeNewsWire • Nov 4, 2026

BillionToOne (BLLN) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks Investment Research • Nov 5, 2026

BillionToOne (BLLN) Surpasses Q3 Earnings and Revenue Estimates
BillionToOne (BLLN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.
Zacks Investment Research • Nov 5, 2026

BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share
BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy, bypassing paternal testing and expanding to 130 genes, outpacing competitors like Natera. Oncology testing is accelerating (176% y/y growth), with Northstar Response's Medicare coverage decision by end-2026 as a key catalyst.
Seeking Alpha • Oct 29, 2026

BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growth
BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell BillionToOne Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.